<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Familial hypercholesterolemia in children</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Familial hypercholesterolemia in children</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Familial hypercholesterolemia in children</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sarah D de Ferranti, MD, MPH</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Ilse Luirink, MD, PhD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David R Fulton, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Carrie Armsby, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Sep 18, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H3487798982"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Familial hypercholesterolemia (FH) is a common autosomal codominant genetic disease. The clinical syndrome (phenotype) is characterized by:</p><p class="bulletIndent1"><span class="glyph">●</span>Elevated low-density lipoprotein cholesterol level from birth</p><p class="bulletIndent1"><span class="glyph">●</span>Xanthomata in untreated adults and children with homozygous FH  (<a class="graphic graphic_picture graphicRef52572 graphicRef50109 graphicRef71083" href="/d/graphic/52572.html" rel="external">picture 1A-C</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Increased risk of premature atherosclerotic cardiovascular disease (ASCVD)</p><p></p><p>The diagnosis and management of FH presenting during childhood will be reviewed here. A broader discussion of pediatric lipid disorders, including our approach to screening for FH and other pediatric dyslipidemias, is provided in a separate topic review. (See  <a class="medical medical_review" href="/d/html/16972.html" rel="external">"Dyslipidemia in children and adolescents: Definition, screening, and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/17048.html" rel="external">"Dyslipidemia in children and adolescents: Management"</a>.)</p><p>The diagnosis, evaluation, and treatment of FH in adults are also discussed separately. (See  <a class="medical medical_review" href="/d/html/107507.html" rel="external">"Familial hypercholesterolemia in adults: Overview"</a> and  <a class="medical medical_review" href="/d/html/111815.html" rel="external">"Familial hypercholesterolemia in adults: Treatment"</a>.) </p><p class="headingAnchor" id="H2119168480"><span class="h1">PREVALENCE</span><span class="headingEndMark"> — </span>Reported prevalence rates of FH vary depending on the definition used and the population studied. Heterozygous FH (HeFH) is estimated to occur in approximately 1 in 200 to 300 individuals [<a href="#rid1">1-4</a>]. In contrast, homozygous FH (HoFH) is rare with an estimated prevalence of approximately 1:300,000 to 1:400,000 [<a href="#rid5">5</a>]. The prevalence of FH is discussed in greater detail separately. (See  <a class="medical medical_review" href="/d/html/107507.html" rel="external">"Familial hypercholesterolemia in adults: Overview", section on 'Prevalence'</a>.)</p><p class="headingAnchor" id="H696276670"><span class="h1">GENETICS</span><span class="headingEndMark"> — </span>FH is most commonly caused by mutations in the low-density lipoprotein receptor gene (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F606945&amp;token=87jLzclRwWxNoI%2BQq5Gg77PTiBtXi5UELpL7sFEdIaQj8R3pxUga6gijgaK9sk%2FA&amp;TOPIC_ID=121831" target="_blank">LDLR</a>). The phenotype of FH can also be seen with mutations in the genes that code for proprotein convertase subtilisin kexin 9 (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F607786&amp;token=87jLzclRwWxNoI%2BQq5Gg72mPAbtE46x%2BrGWSY2Cu7YrsKFLCI6KYO%2BPbycDGHod%2F&amp;TOPIC_ID=121831" target="_blank">PCSK9</a>) and apolipoprotein B (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F107730&amp;token=87jLzclRwWxNoI%2BQq5Gg75q2gGI0nOmFu5TwNFUmVKBmxmGgIVZUk%2BKw6IkUW%2BsL&amp;TOPIC_ID=121831" target="_blank">APOB</a>). Individuals with phenotypic FH who do not have mutations in one of these key causative mutations may have polygenetic defects. FH is inherited with a gene dosing effect, in which homozygotes are more adversely affected than heterozygotes  (<a class="graphic graphic_figure graphicRef105115" href="/d/graphic/105115.html" rel="external">figure 1</a>). The genetics of FH are discussed in greater detail separately. (See  <a class="medical medical_review" href="/d/html/107507.html" rel="external">"Familial hypercholesterolemia in adults: Overview", section on 'Genetic considerations'</a>.)</p><p class="headingAnchor" id="H2322542551"><span class="h1">SCREENING</span><span class="headingEndMark"> — </span>The first step in FH screening is usually a lipid profile. In fact, an important goal of lipid screening in childhood and adolescence is to identify and treat individuals with FH, a group at high risk for morbidity and early mortality. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Universal screening</strong> – Universal lipid screening is suggested twice during childhood/adolescence (once between the age of 9 and 11 years and again between age 17 and 21 years) to identify FH. Earlier and more frequent lipid screening is appropriate for children with a family history of premature atherosclerotic cardiovascular disease (ASCVD) or high cholesterol. The approach to lipid screening in children and adolescents is summarized in the algorithms and is discussed in greater detail separately  (<a class="graphic graphic_algorithm graphicRef105367 graphicRef121848" href="/d/graphic/105367.html" rel="external">algorithm 1A-B</a>). (See  <a class="medical medical_review" href="/d/html/16972.html" rel="external">"Dyslipidemia in children and adolescents: Definition, screening, and diagnosis", section on 'Approach to screening'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cascade screening </strong>– Children with a family history of premature ASCVD or very high cholesterol should be tested for FH as early as age two years. Identification of one family member with FH, either by lipid values or by molecular diagnosis, should prompt screening of other first- and second-degree relatives (eg, cascade screening). (See <a class="local">'Testing family members'</a> below.)</p><p></p><p class="headingAnchor" id="H314303276"><span class="h1">EVALUATION</span></p><p class="headingAnchor" id="H1806887315"><span class="h2">Clinical suspicion</span><span class="headingEndMark"> — </span>A diagnosis of FH should be suspected in the following settings [<a href="#rid1">1,6,7</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Elevated plasma low-density lipoprotein cholesterol (LDL-C) in the child – The level of LDL-C that warrants further evaluation depends upon whether additional family members have known hypercholesterolemia or premature atherosclerotic cardiovascular disease (ASCVD):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In patients with a negative or unknown family history, an LDL-C level of ≥190 mg/dL (4.9 mmol/L) suggests FH</p><p class="bulletIndent2"><span class="glyph">•</span>In patients with a positive family history of hypercholesterolemia and/or premature ASCVD, an LDL-C level of ≥160 mg/dL (4.1 mmol/L) is suggestive of FH.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Elevated plasma LDL-C or known FH in family members (total cholesterol [TC] &gt;240 mg/dL [6.2 mmol/L] in either parent). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Tendon xanthomas in the child or family member(s).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Premature ASCVD in the child or family member(s) – Premature ASCVD is generally defined as any of the following before age 55 years in males or before age 65 years in females: </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Heart attack</p><p class="bulletIndent2"><span class="glyph">•</span>Treated angina</p><p class="bulletIndent2"><span class="glyph">•</span>Interventions for coronary artery disease (CAD)</p><p class="bulletIndent2"><span class="glyph">•</span>Sudden cardiac death</p><p class="bulletIndent2"><span class="glyph">•</span>Ischemic stroke </p><p></p><p class="headingAnchor" id="H4106054380"><span class="h2">Evaluation</span><span class="headingEndMark"> — </span>Evaluation of a child or adolescent with suspected FH includes the following:</p><p class="headingAnchor" id="H2314057223"><span class="h3">Family history</span><span class="headingEndMark"> — </span>A detailed family history is essential in establishing the diagnosis of FH. Identifying family members with premature ASCVD, tendon xanthomas, and elevated cholesterol levels (particularly if present during childhood) helps support the diagnosis of FH. The historian should ask about siblings, parents, aunts, uncles, and grandparents; information about more distant relatives may also be informative.</p><p class="headingAnchor" id="H2453817214"><span class="h3">Physical examination</span><span class="headingEndMark"> — </span>The physical examination is directed at identifying abnormal deposits of cholesterol in the skin and eyes. These are rarely seen in children except in individuals with homozygous FH and certain other rare genetic conditions (eg, sitosterolemia, cerebrotendinous xanthomatosis) (see <a class="local">'Differential diagnosis'</a> below):</p><p class="bulletIndent1"><span class="glyph">●</span>Tendon xanthomata  (<a class="graphic graphic_picture graphicRef52572 graphicRef50109 graphicRef71083" href="/d/graphic/52572.html" rel="external">picture 1A-C</a>) are most common in the Achilles tendons and dorsum of the hands but can occur at other sites. Tendon xanthomata in children are highly suggestive of homozygous FH (HoFH).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Tuberous xanthomata  (<a class="graphic graphic_picture graphicRef111542 graphicRef72875" href="/d/graphic/111542.html" rel="external">picture 2A-B</a>) typically occur over extensor surfaces such as the knee and elbow.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Planar xanthomas  (<a class="graphic graphic_picture graphicRef67239" href="/d/graphic/67239.html" rel="external">picture 3</a>) may occur on the palms of the hands and soles of the feet and are often painful.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Xanthelasmas  (<a class="graphic graphic_picture graphicRef67919" href="/d/graphic/67919.html" rel="external">picture 4</a>) are cholesterol-filled, soft, yellow plaques that usually appear on the medial aspects of the eyelids.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Corneal arcus  (<a class="graphic graphic_picture graphicRef95255" href="/d/graphic/95255.html" rel="external">picture 5</a>) is a white or grey ring around the cornea.</p><p></p><p class="headingAnchor" id="H2573305615"><span class="h3">Lipid profile</span><span class="headingEndMark"> — </span>The characteristic fasting lipid profile in patients with FH consists of (see <a class="local">'Clinical suspicion'</a> above):</p><p class="bulletIndent1"><span class="glyph">●</span>Elevated TC</p><p class="bulletIndent1"><span class="glyph">●</span>Elevated LDL-C</p><p class="bulletIndent1"><span class="glyph">●</span>Normal or low high-density lipoprotein cholesterol (HDL-C)</p><p class="bulletIndent1"><span class="glyph">●</span>Normal triglyceride (TG) levels unless the child is obese, in which case TG levels may be elevated. Elevated TG levels do not exclude the diagnosis of FH; however, other potential causes of hypertriglyceridemia should be considered.</p><p></p><p class="headingAnchor" id="H3020648475"><span class="h3">Evaluate for secondary causes</span><span class="headingEndMark"> — </span>An evaluation for secondary causes of hypercholesterolemia  (<a class="graphic graphic_table graphicRef71294" href="/d/graphic/71294.html" rel="external">table 1</a>) should be performed as described separately. (See  <a class="medical medical_review" href="/d/html/16972.html" rel="external">"Dyslipidemia in children and adolescents: Definition, screening, and diagnosis", section on 'Secondary causes of hypercholesterolemia'</a>.)</p><p class="headingAnchor" id="H353462649"><span class="h3">Genetic testing</span><span class="headingEndMark"> — </span>Testing for mutations in the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F606945&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdyqZvH8B67zc54PCoQNakQYi&amp;TOPIC_ID=121831" target="_blank"><i>LDLR</i></a>, <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F107730&amp;token=tEpDslnpc0F0kICl%2Fz7sFc8JblQ%2BgdQqT9K%2Br8tS8tjdlf01kAfyT8%2B%2FbsYKwVdF&amp;TOPIC_ID=121831" target="_blank"><i>APOB</i></a>, and <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F607786&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdyqAswF%2Bh2WgQ41BBcelnzoq&amp;TOPIC_ID=121831" target="_blank"><i>PCSK9</i></a> genes should be offered to pediatric patients with xanthomata or a clinical picture of HoFH based on the criteria discussed below [<a href="#rid1">1</a>]. (See <a class="local">'Homozygous FH (HoFH)'</a> below.)</p><p>The benefits of genetic testing in children whose clinical picture is consistent with heterozygous FH (HeFH) is less clear and its role in the diagnosis and treatment of this population is evolving. Potential benefits of genetic testing in HeFH include improved adherence to recommended therapy, impact on cascade screening of relatives, and counseling the parents about future pregnancies. In addition, genetic testing provides clarity in the diagnosis, which may guide management decisions, particularly regarding use of statin therapy for individuals with borderline LDL-C levels.</p><p>Genetic testing should be performed in consultation with a lipid specialist and/or geneticist.</p><p class="headingAnchor" id="H3726541093"><span class="h1">DIAGNOSIS</span></p><p class="headingAnchor" id="H3357208177"><span class="h2">Heterozygous FH (HeFH)</span><span class="headingEndMark"> — </span>The diagnosis of HeFH can be made clinically and through molecular genetic testing.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical diagnosis</strong> – The clinical diagnosis of heterozygous FH is generally based on [<a href="#rid8">8</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>High levels of total and LDL-C, <strong>plus</strong> one or more of the following:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Family history of hypercholesterolemia (especially in children) or known FH</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>History of premature ASCVD in the patient or in family members</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Physical examination findings of abnormal deposition of cholesterol in extravascular tissues (eg, tendon xanthoma  (<a class="graphic graphic_picture graphicRef52572 graphicRef50109" href="/d/graphic/52572.html" rel="external">picture 1A-B</a>)), although these rarely occur in childhood</p><p></p><p class="bulletIndent1">Different definitions of FH are used in different parts of the world, and there is some variation in diagnostic criteria: </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The American Heart Association (AHA) criteria [<a href="#rid8">8</a>]:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>LDL-C ≥155 mg/dL (4 mmol/L), <strong>plus</strong> </p><p class="bulletIndent3"><span class="glyph">-</span>Positive family history of elevated LDL-C or premature ASCVD, <strong>plus</strong></p><p class="bulletIndent3"><span class="glyph">-</span>Exclusion of secondary causes of hypercholesterolemia </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Simon Broome Register Group  (<a class="graphic graphic_table graphicRef111789" href="/d/graphic/111789.html" rel="external">table 2</a>) [<a href="#rid9">9</a>] </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Dutch Lipid Clinic Network (DLCN) criteria, applicable to adult patients  (<a class="graphic graphic_table graphicRef88939" href="/d/graphic/88939.html" rel="external">table 3</a>) [<a href="#rid1">1</a>]</p><p></p><p class="bulletIndent1">In our practice, we typically use the AHA criteria. Simon Broome criteria are used predominately in the United Kingdom. The DLCN criteria do not include pediatric criteria and are not applicable in childhood. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Molecular diagnosis</strong> – A definitive diagnosis of heterozygous FH can be made by identifying a causative mutation in the, and genes. However, genetic testing is not required to establish the diagnosis. (See <a class="local">'Genetic testing'</a> above.)</p><p></p><p class="headingAnchor" id="H3456885928"><span class="h2">Homozygous FH (HoFH)</span><span class="headingEndMark"> — </span>Genetic testing should be performed in individuals with suspected homozygous FH.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical suspicion</strong> – Homozygous FH should be suspected in individuals who meet the following criteria [<a href="#rid10">10</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Untreated LDL-C &gt;500 mg/dL (&gt;13 mmol/L) or treated LDL-C ≥300 mg/dL (&gt;8 mmol/L), <strong>plus</strong> either of the following:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Cutaneous or tendon xanthoma  (<a class="graphic graphic_picture graphicRef52572 graphicRef50109" href="/d/graphic/52572.html" rel="external">picture 1A-B</a>) before age 10 years, <strong>or</strong></p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Elevated LDL-C levels consistent with heterozygous FH in both parents</p><p></p><p class="bulletIndent1">It is important to note that untreated LDL-C levels &lt;500 mg/dL (12.9 mmol/L) may be seen in some individuals with homozygous FH, particularly in very young children, and genetic testing should be considered to make the diagnosis of homozygous FH.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Molecular diagnosis</strong> – The definitive diagnosis of homozygous FH is established by identifying causative mutation(s) in the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F606945&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdyqZvH8B67zc54PCoQNakQYi&amp;TOPIC_ID=121831" target="_blank"><i>LDLR</i></a>, <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F107730&amp;token=tEpDslnpc0F0kICl%2Fz7sFc8JblQ%2BgdQqT9K%2Br8tS8tjdlf01kAfyT8%2B%2FbsYKwVdF&amp;TOPIC_ID=121831" target="_blank"><i>APOB</i></a>, and <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F607786&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdyqAswF%2Bh2WgQ41BBcelnzoq&amp;TOPIC_ID=121831" target="_blank"><i>PCSK9</i></a> genes.</p><p></p><p class="headingAnchor" id="H2123648715"><span class="h2">Testing family members</span><span class="headingEndMark"> — </span>Once FH is diagnosed, either by clinically or with molecular testing, it is appropriate to test other family members to see if they are affected. This is referred to as "cascade screening." Testing is performed in first- and second-degree relatives (eg, siblings, parents, grandparents, aunts, and uncles). Testing can be accomplished using a fasting lipid profile or a nonfasting TC and HDL-C. If molecular diagnosis has been made, targeted genetic testing for the specific defect is appropriate, along with a lipid profile to assess the need for lipid lowering treatment.</p><p class="headingAnchor" id="H3955113426"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>It is important to distinguish FH from other causes of hypercholesterolemia, xanthomata, and/or premature atherosclerotic cardiovascular disease (ASCVD):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hypercholesterolemia and premature ASCVD</strong> – Other causes of hypercholesterolemia and premature ASCVD include  (<a class="graphic graphic_table graphicRef66747" href="/d/graphic/66747.html" rel="external">table 4</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Familial combined hyperlipidemia (see  <a class="medical medical_review" href="/d/html/4567.html" rel="external">"Inherited disorders of LDL-cholesterol metabolism other than familial hypercholesterolemia", section on 'Familial combined hyperlipidemia'</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Familial hyperapobetalipoproteinemia (likely a variant of familial combined hyperlipidemia)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Polygenic hypercholesterolemia (see  <a class="medical medical_review" href="/d/html/4567.html" rel="external">"Inherited disorders of LDL-cholesterol metabolism other than familial hypercholesterolemia", section on 'Polygenic hypercholesterolemia'</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Familial dysbetalipoproteinemia (type III hyperlipoproteinemia) (see  <a class="medical medical_review" href="/d/html/132419.html" rel="external">"Hypertriglyceridemia in adults: Approach to evaluation", section on 'Etiology'</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Secondary causes of dyslipidemia  (<a class="graphic graphic_table graphicRef71294" href="/d/graphic/71294.html" rel="external">table 1</a>) and premature atherosclerosis (see  <a class="medical medical_review" href="/d/html/5781.html" rel="external">"Overview of risk factors for development of atherosclerosis and early cardiovascular disease in childhood"</a>)</p><p></p><p class="bulletIndent1">The clinical history and evaluation of the lipid profile are helpful in distinguishing these disorders.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Xanthomata</strong> – Xanthomata in children are highly suggestive of homozygous FH, but they can be seen on other rare genetic disorders such as sitosterolemia and cerebrotendinous xanthomatosis, described below. In addition, juvenile xanthogranulomas (JXG)  (<a class="graphic graphic_picture graphicRef69122 graphicRef68132" href="/d/graphic/69122.html" rel="external">picture 6A-B</a>) and other non-Langerhans cell histiocytoses have a similar appearance and may be mistaken for xanthomata. The distribution of the lesions helps to differentiate xanthomata in FH from the lesions in JXG (in FH, xanthomata commonly occur on Achilles tendons, dorsum of the hands, and extensor surfaces of the knees and elbows, whereas lesions in JXG typically occur on the head, neck, and upper trunk). A definitive distinction is made on the basis of the lipid profile, which is normal in JXG. (See  <a class="medical medical_review" href="/d/html/13729.html" rel="external">"Juvenile xanthogranuloma (JXG)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tendon xanthomata and premature atherosclerosis</strong> – Tendon xanthomata and premature atherosclerosis can also occur in several rare genetic disorders:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F210250&amp;token=87jLzclRwWxNoI%2BQq5Gg76V7mmZK0n5PcthlVLa09D5nsgSEl6HFm%2F4IYMj0qOOH&amp;TOPIC_ID=121831" target="_blank">Sitosterolemia</a> – Sitosterolemia (alternatively termed "phytosterolemia") is an autosomal recessive disorder associated with hyperabsorption of cholesterol and plant sterols from the intestine [<a href="#rid11">11</a>]. It is characterized by tendinous and/or tuberous xanthomas in childhood associated with high plasma cholesterol and atherosclerotic complications. Sitosterolemia can be differentiated from FH based upon markedly (&gt;30-fold) increased plasma concentrations of plant sterols. In addition, patients with sitosterolemia typically respond well to diet restricting plant-based mono and polyunsaturated fats, bile acid sequestrants, and <a class="drug drug_pediatric" data-topicid="12909" href="/d/drug information/12909.html" rel="external">ezetimibe</a>, which generally is not the case in patients with homozygous FH. Diagnosis of sitosterolemia is confirmed by genetic analysis, with detection of mutations in two adenosine triphosphate -binding cassette transporter (ABC transporters) genes, <em>ABCG5</em>, and/or <em>ABCG8</em> [<a href="#rid10">10</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F213700&amp;token=87jLzclRwWxNoI%2BQq5Gg70jd%2BGF1VdkFmUwxxw2XKWiaa2fuBpSdd5VQ6aUYEshQ&amp;TOPIC_ID=121831" target="_blank">Cerebrotendinous xanthomatosis</a> – Cerebrotendinous xanthomatosis is caused by a block in bile acid synthesis due to the absence of hepatic mitochondrial 27-hydroxylase (CYP27A1). It can be distinguished from FH by the presence of neurologic, cognitive, and ophthalmic symptoms and usually normal serum cholesterol concentrations. (See  <a class="medical medical_review" href="/d/html/1692.html" rel="external">"Cerebrotendinous xanthomatosis"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F278000&amp;token=tEpDslnpc0F0kICl%2Fz7sFbhJ8i4i2PcUPvJ4%2FzB1yQa8COV60Vod5nxZfZzu1KCH&amp;TOPIC_ID=121831" target="_blank">Lysosomal acid lipase deficiency</a> – Lysosomal acid lipase deficiency (also called cholesterol ester storage disease) is an autosomal recessive disorder in which low-density lipoprotein cholesterol levels are elevated (typically in the range of 200 to 300 mg/dL) with low high-density lipoprotein cholesterol levels and elevated triglycerides [<a href="#rid12">12</a>]. Additional characteristic findings in affected children may include hepatosplenomegaly and elevated liver enzymes. Xanthomata and premature atherosclerosis can occur, but these findings are generally not seen until adulthood. The diagnosis is confirmed with molecular testing and enzyme activity assays. (See  <a class="medical medical_review" href="/d/html/115661.html" rel="external">"Metabolic dysfunction-associated steatotic liver disease in children and adolescents"</a>.)</p><p></p><p class="headingAnchor" id="H246088200"><span class="h1">MANAGEMENT</span></p><p class="headingAnchor" id="H1855925604"><span class="h2">Management of HeFH</span><span class="headingEndMark"> — </span>Children and adolescents with heterozygous FH (HeFH) have an increased risk of premature atherosclerotic cardiovascular disease (ASCVD). They should generally be referred to a pediatric lipid specialist (if available) and treated aggressively [<a href="#rid6">6,13</a>]. A pediatric lipid specialist is typically pediatric cardiologist (or an endocrinologist, gastroenterologist, or general pediatrician), who has completed additional training in lipid disorders through a senior fellowship or via professional societies. If a pediatric lipid specialist is not available locally, referral to an adult lipid specialist may be helpful, particularly for adolescents. </p><p>The practice presented in the following sections is generally consistent with the 2019 American Heart Association (AHA) scientific statement on cardiovascular risk reduction in high-risk pediatric patients, the 2018 American College of Cardiology/AHA cholesterol guidelines, and the 2014 European Atherosclerosis Society FH guidelines [<a href="#rid10">10,13,14</a>]. Links to these and other society guidelines are provided separately. (See <a class="local">'Society guideline links'</a> below.)</p><p>Additional details regarding statins and other lipid lowering therapies in children are provided separately. (See  <a class="medical medical_review" href="/d/html/17048.html" rel="external">"Dyslipidemia in children and adolescents: Management", section on 'Statin therapy'</a> and  <a class="medical medical_review" href="/d/html/17048.html" rel="external">"Dyslipidemia in children and adolescents: Management", section on 'Second-line agents and other therapies'</a>.)</p><p class="headingAnchor" id="H2789529866"><span class="h3">Treatment goals</span><span class="headingEndMark"> — </span>The management approach in children with HeFH is generally similar to the management of other causes of pediatric hypercholesterolemia, which is summarized in the algorithms  (<a class="graphic graphic_algorithm graphicRef106010 graphicRef106011" href="/d/graphic/106010.html" rel="external">algorithm 2A-B</a>) and discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/17048.html" rel="external">"Dyslipidemia in children and adolescents: Management", section on 'Hypercholesterolemia'</a>.)</p><p>For children and adolescents with HeFH, a combination of lifestyle and medical management is generally required to sufficiently lower LDL-C. The goal of treatment is to reduce LDL-C minimally to a level &lt;130 mg/dL (3.4 mmol/L) and ideally below 100 mg/dL (2.6 mmol/L). This usually represent a 50 percent reduction (approximately) from pretreatment levels.</p><p class="headingAnchor" id="H3077926779"><span class="h3">Key distinctions between HeFH and other types of dyslipidemia</span><span class="headingEndMark"> — </span>Although the management approach for children with HeFH is generally similar to the general approach, there are some key distinctions in children with HeFH:</p><p class="bulletIndent1"><span class="glyph">●</span>Children with HeFH are unlikely to respond sufficiently to dietary modification alone and therefore they are likely to require statin therapy. (See  <a class="medical medical_review" href="/d/html/17048.html" rel="external">"Dyslipidemia in children and adolescents: Management", section on 'Statin therapy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Children with HeFH may benefit from statin therapy at an earlier age (as early as age eight depending on low-density lipoprotein cholesterol [LDL-C] levels and family history of ASCVD).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Children with HeFH are more likely to require a second lipid-lowering agent in addition to statin therapy, although high-intensity statin at moderate to high doses is often sufficient. In our practice, when a second agent is required, we typically initiate <a class="drug drug_pediatric" data-topicid="12909" href="/d/drug information/12909.html" rel="external">ezetimibe</a> for the reasons discussed separately. (See  <a class="medical medical_review" href="/d/html/17048.html" rel="external">"Dyslipidemia in children and adolescents: Management", section on 'Second-line agents and other therapies'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Children with HeFH are likely to have affected family members. Thus, testing should be offered to first- and second-degree relatives of individuals with FH. (See <a class="local">'Testing family members'</a> above.)</p><p></p><p class="headingAnchor" id="H215245986"><span class="h3">Timing for initiating treatment</span><span class="headingEndMark"> — </span>The optimal age at which to initiate treatment of children with HeFH is unknown. Many clinicians begin therapy at age 10 years based upon prospective studies suggesting that differences in preclinical markers of atherosclerosis (eg, carotid intima-media thickness [CIMT]) between children with HeFH and their unaffected siblings are detectable starting at approximately age 10 years of age [<a href="#rid15">15,16</a>]. If the LDL-C elevations are severe, the family history is particularly concerning, and lifestyle modification is not effective, treatment can be started before age 10 years under the care of a pediatric lipid specialist.</p><p class="headingAnchor" id="H2242046467"><span class="h3">Benefits of statin therapy</span><span class="headingEndMark"> — </span>Clinical trials and meta-analyses of randomized trials have found that statin therapy in children with HeFH reduces LDL-C levels by approximately 25 to 40 percent, depending on dose and potency [<a href="#rid17">17-19</a>]. In the available trials, rates of adverse effects (ie, hepatic and muscular toxicity) in children treated with statins were similar to those treated with placebo, and no effects on sexual development were seen [<a href="#rid18">18,19</a>]. No serious adverse events were reported in one study with 20-year follow-up, though 2 percent stopped taking the drug due to adverse side effects [<a href="#rid20">20</a>].</p><p>Some studies have also demonstrated improvements in preclinical markers of atherosclerosis, including CIMT and flow-mediated dilation (FMD), a measure of endothelial function [<a href="#rid15">15,17,21-23</a>].</p><p class="bulletIndent1">The most compelling evidence for the benefits of statin therapy in children with FH comes from a clinical trial in which 214 children with HeFH were randomly assigned to treatment with a statin (<a class="drug drug_pediatric" data-topicid="12913" href="/d/drug information/12913.html" rel="external">pravastatin</a>) or placebo [<a href="#rid21">21</a>]. The initial trial ran for two years, after which most patients in the placebo arm were switched to a statin. The children enrolled in the trial and their unaffected siblings were then followed for 20 years to assess the long-term effects of statin therapy [<a href="#rid15">15,20,22</a>]. In the original trial, pravastatin reduced LDL-C by 24 percent and children treated with a pravastatin had regression in CIMT, while patients treated with placebo demonstrated the expected progression of increased CIMT [<a href="#rid21">21</a>]. Two follow-up reports suggested that earlier intervention delayed progression of preclinical atherosclerosis and slowed the rate of CIMT progression to levels comparable with those of their unaffected siblings [<a href="#rid15">15,22</a>]. In a report of 20-year follow-up of 184 patients enrolled in the original trial and 77 of their unaffected siblings, the benefits of starting statin therapy in childhood on lowering LDL-C and slowing progression of CIMT persisted into adulthood such that the rate of CIMT progression was identical to that of unaffected siblings [<a href="#rid20">20</a>]. To assess whether early initiation of statin therapy in childhood was associated with a lower rate of cardiovascular events in adulthood, the investigators compared cardiovascular outcomes in the trial participants (n = 203) with outcomes of their parents who were also affected by HeFH (n = 156) but for whom statins were only available much later in life. Trial participants had considerably fewer cardiovascular events by age 40 years compared with their affected parents (1 versus 26 percent).</p><p></p><p class="bulletIndent1">Other clinical trials have also demonstrated medium-term benefits in reducing subclinical vascular changes in children with FH [<a href="#rid17">17,23</a>].</p><p></p><p class="headingAnchor" id="H764729830"><span class="h3">Other agents</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ezetimibe</strong><strong> </strong>– Studies in adolescents and adults with HeFH have demonstrated that the combination of a statin plus <a class="drug drug_pediatric" data-topicid="12909" href="/d/drug information/12909.html" rel="external">ezetimibe</a> lowers LDL-C to a greater extent than monotherapy with statin [<a href="#rid24">24,25</a>]. In a study of 248 male and female adolescents with HeFH, combination <a class="drug drug_pediatric" data-topicid="12928" href="/d/drug information/12928.html" rel="external">ezetimibe-simvastatin</a> reduced LDL-C by an additional 15 percent and was not associated with increased risk of adverse events compared with a similar dose of <a class="drug drug_pediatric" data-topicid="12792" href="/d/drug information/12792.html" rel="external">simvastatin</a> monotherapy during up to 53 weeks of therapy [<a href="#rid25">25</a>]. (See  <a class="medical medical_review" href="/d/html/17048.html" rel="external">"Dyslipidemia in children and adolescents: Management", section on 'Second-line agents and other therapies'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>PCSK9 inhibitors</strong> – Use of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors (eg, <a class="drug drug_pediatric" data-topicid="129290" href="/d/drug information/129290.html" rel="external">evolocumab</a> and <a class="drug drug_general" data-topicid="103073" href="/d/drug information/103073.html" rel="external">alirocumab</a>) is generally limited to patients with persistently elevated LDL-C despite treatment with maximal statin therapy and those who cannot tolerate maximal statin therapy. In the United States, evolocumab is approved for use in patients aged ≥10 years with HeFH or HoFH [<a href="#rid26">26</a>]; alirocumab is approved only for use in adult patients. In Europe, evolocumab is approved for use in patients ≥12 years old with homozygous FH [<a href="#rid27">27</a>]. In a randomized trial involving 157 adolescent patients with HeFH, evolocumab reduced LDL-C levels by approximately 40 percent relative to placebo [<a href="#rid28">28</a>]. (See  <a class="medical medical_review" href="/d/html/106888.html" rel="external">"PCSK9 inhibitors: Pharmacology, adverse effects, and use"</a>.) </p><p></p><p></p><p class="headingAnchor" id="H812533616"><span class="h2">Management of HoFH</span><span class="headingEndMark"> — </span>Children with clinically suspected homozygous FH (HoFH) based on phenotype (ie, untreated LDL-C ≥500 mg/dL [12.9 mmol/L]) or confirmed HoFH by genetic testing, should be managed by a pediatric lipid specialist and a pediatric cardiologist. </p><p class="headingAnchor" id="H607774492"><span class="h3">Comprehensive cardiovascular evaluation</span><span class="headingEndMark"> — </span>Children with HoFH should undergo a comprehensive cardiovascular evaluation at diagnosis and at periodic follow-up. Testing includes:</p><p class="bulletIndent1"><span class="glyph">●</span>Electrocardiogram.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Echocardiography to evaluate for supravalvar aortic stenosis and for left ventricular dysfunction including segmental wall motion abnormalities.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Functional testing (ie, exercise stress testing, including stress echocardiography looking for segmental wall motion abnormalities and function augmentation) if child is old enough to cooperate with such testing.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Coronary artery imaging – In our practice, we perform coronary angiography at the time of diagnosis to establish the child's baseline and to guide the intensity of lipid lowering therapies. Angiography is then performed every two to three years depending on the degree of lipid lowering and index of suspicion with regard to clinically manifest atherosclerosis. A low threshold for evaluation is warranted since signs and symptoms of myocardial ischemia in children are often "atypical" (eg, nausea, vomiting, pallor, sweating, throat pain, and ear pain with or without accompanying chest pain). Coronary angiography can be performed invasively via cardiac catheterization or noninvasively with computed tomography (CT). CT angiography is a useful alternative to invasive angiography because of its ability to demonstrate atherosclerotic plaque beyond coronary lumen dimensions [<a href="#rid29">29</a>].</p><p></p><p class="headingAnchor" id="H1860701907"><span class="h3">Management principles</span><span class="headingEndMark"> — </span>Children and adolescents with HoFH should receive prompt and aggressive lipid-lowering therapy beginning at the time of diagnosis [<a href="#rid8">8,10,13</a>].</p><p>Management is carried out in a stepwise fashion targeting a goal LDL-C value of &lt;135 mg/dL (3.5 mmol/L) [<a href="#rid10">10</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>High potency statin therapy should be initiated along with lifestyle advice at the time of diagnosis, even in infancy. (See  <a class="medical medical_review" href="/d/html/17048.html" rel="external">"Dyslipidemia in children and adolescents: Management", section on 'Dietary modification'</a> and  <a class="medical medical_review" href="/d/html/17048.html" rel="external">"Dyslipidemia in children and adolescents: Management", section on 'Statin therapy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Most patients with HoFH only achieve modest reductions in LDL-C levels with diet and statin therapy, even at maximal doses. <a class="drug drug_pediatric" data-topicid="12909" href="/d/drug information/12909.html" rel="external">Ezetimibe</a> is initiated as an additional treatment early on. Bile acid sequestrants or nicotinic acid are alternatives, but compliance with these agents is often poor. (See  <a class="medical medical_review" href="/d/html/17048.html" rel="external">"Dyslipidemia in children and adolescents: Management", section on 'Second-line agents and other therapies'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Additional treatments are invariably required. These include anti-<em>PCSK9</em> therapy, <a class="drug drug_pediatric" data-topicid="130801" href="/d/drug information/130801.html" rel="external">evinacumab</a>, LDL apheresis, and <a class="drug drug_general" data-topicid="87508" href="/d/drug information/87508.html" rel="external">lomitapide</a>. Use of anti-<em>PCSK9</em> therapy depends in part on the genetic diagnosis; it is generally <strong>not</strong> effective for patients with null LDL-R defects. Evinacumab, an antibody therapy directed against <em>ANGPTL3</em>, lowers LDL independent of the LDL receptor, making it an effective therapy in those with null defects [<a href="#rid30">30-32</a>]. Liver transplant has been described as a last resort intervention, though this is rarely necessary in the modern era with the availability of newer lipid-lowering drugs [<a href="#rid33">33</a>]. In our experience, most patients with homozygous FH achieve adequate lipid lowering with a combination of statin, <a class="drug drug_pediatric" data-topicid="12909" href="/d/drug information/12909.html" rel="external">ezetimibe</a>, LDL apheresis, <em>PCSK9</em> inhibitors (if there is any LDL receptor function), evinacumab, and lomitapide. (See  <a class="medical medical_review" href="/d/html/17048.html" rel="external">"Dyslipidemia in children and adolescents: Management", section on 'Second-line agents and other therapies'</a> and  <a class="medical medical_review" href="/d/html/4554.html" rel="external">"Treatment of drug-resistant hypercholesterolemia"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In addition to lipid-lowering therapy, low-dose <a class="drug drug_pediatric" data-topicid="12829" href="/d/drug information/12829.html" rel="external">aspirin</a> and beta blocker therapy are appropriate for children with established atherosclerotic coronary artery disease (CAD) based on the established benefits of these drugs in adults with CAD. (See  <a class="medical medical_review" href="/d/html/110006.html" rel="external">"Aspirin for the secondary prevention of atherosclerotic cardiovascular disease"</a> and  <a class="medical medical_review" href="/d/html/1466.html" rel="external">"Beta blockers in the management of chronic coronary syndrome"</a>.)</p><p></p><p class="headingAnchor" id="H971945636"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/110734.html" rel="external">"Society guideline links: Lipid disorders and atherosclerosis in children"</a>.)</p><p class="headingAnchor" id="H1479570527"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition</strong> – Familial hypercholesterolemia (FH) is a common autosomal codominant genetic disease. The clinical syndrome (phenotype) is characterized by (see <a class="local">'Introduction'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Elevated low-density lipoprotein cholesterol (LDL-C) level from birth.</p><p class="bulletIndent2"><span class="glyph">•</span>Xanthomata in untreated adults and younger individuals with homozygous FH  (<a class="graphic graphic_picture graphicRef52572 graphicRef50109 graphicRef71083" href="/d/graphic/52572.html" rel="external">picture 1A-C</a>).</p><p class="bulletIndent2"><span class="glyph">•</span>Increased risk of premature atherosclerotic cardiovascular disease (ASCVD). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Genetics</strong> – FH is inherited with a gene-dosing effect, in which homozygotes are more adversely affected than heterozygotes  (<a class="graphic graphic_figure graphicRef105115" href="/d/graphic/105115.html" rel="external">figure 1</a>). Homozygotes generally manifest coronary artery disease (CAD) in childhood; untreated homozygous FH (HoFH) is life threatening. (See <a class="local">'Genetics'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevalence</strong> – Heterozygous FH (HeFH) is estimated to occur in approximately 1 in 200 to 300 individuals. In contrast, HoFH is rare, with an estimated prevalence of approximately 1:300,000 to 1:400,000. (See <a class="local">'Prevalence'</a> above and  <a class="medical medical_review" href="/d/html/107507.html" rel="external">"Familial hypercholesterolemia in adults: Overview", section on 'Prevalence'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Screening </strong>– Selective, cascade, and universal lipid screening during childhood and adolescence play key roles in identifying and treating individuals with FH. The suggested approach to lipid screening in childhood and adolescence is summarized in the algorithms and is discussed in greater detail separately  (<a class="graphic graphic_algorithm graphicRef105367 graphicRef121848" href="/d/graphic/105367.html" rel="external">algorithm 1A-B</a>). (See  <a class="medical medical_review" href="/d/html/16972.html" rel="external">"Dyslipidemia in children and adolescents: Definition, screening, and diagnosis", section on 'Rationale for lipid screening'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical suspicion</strong> – FH should be suspected in the following settings (see <a class="local">'Clinical suspicion'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>High cholesterol in the child </p><p class="bulletIndent2"><span class="glyph">•</span>High cholesterol or known FH in family members </p><p class="bulletIndent2"><span class="glyph">•</span>Tendon xanthomata in the child or in family members</p><p class="bulletIndent2"><span class="glyph">•</span>Premature ASCVD in the child or in family members</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluation</strong> – Evaluation for FH includes (see <a class="local">'Evaluation'</a> above): </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Detailed family history. (See <a class="local">'Family history'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Physical examination, which in severe cases may show abnormal deposits of cholesterol (eg, tendon xanthomata  (<a class="graphic graphic_picture graphicRef52572 graphicRef50109 graphicRef71083" href="/d/graphic/52572.html" rel="external">picture 1A-C</a>), tuberous xanthomata  (<a class="graphic graphic_picture graphicRef111542 graphicRef72875" href="/d/graphic/111542.html" rel="external">picture 2A-B</a>), xanthelasmas  (<a class="graphic graphic_picture graphicRef67919" href="/d/graphic/67919.html" rel="external">picture 4</a>), corneal arcus  (<a class="graphic graphic_picture graphicRef95255" href="/d/graphic/95255.html" rel="external">picture 5</a>)). (See <a class="local">'Physical examination'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Fasting lipid profile (typical pattern is elevated total cholesterol and LDL-C, with normal or low high-density lipoprotein cholesterol and normal triglycerides). (See <a class="local">'Lipid profile'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Evaluation to exclude secondary causes of elevated LDL-C  (<a class="graphic graphic_table graphicRef71294" href="/d/graphic/71294.html" rel="external">table 1</a>). (See  <a class="medical medical_review" href="/d/html/16972.html" rel="external">"Dyslipidemia in children and adolescents: Definition, screening, and diagnosis", section on 'Secondary causes of hypercholesterolemia'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Genetic testing should be offered to children who have findings consistent with HoFH (ie, xanthomata and/or LDL-C levels &gt;500 mg/dL [&gt;13 mmol/L]). The role of genetic testing in individuals with suspected HeFH is less clear. (See <a class="local">'Genetic testing'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – The diagnosis of FH can be made clinically and/or with molecular genetic testing (see <a class="local">'Diagnosis'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>HeFH</strong> – The clinical diagnosis of HeFH is based on high cholesterol levels in combination with family history of hypercholesterolemia, family or personal history of premature atherosclerotic CVD, and/or physical examination findings of xanthomata (although these rarely occur in childhood). The clinical criteria differ somewhat depending on the specific clinical definition used. Commonly used definitions include the American Heart Association (AHA) criteria, the Simon Broome Register Group  (<a class="graphic graphic_table graphicRef111789" href="/d/graphic/111789.html" rel="external">table 2</a>), and the Dutch Lipid Clinic Network criteria for adults  (<a class="graphic graphic_table graphicRef88939" href="/d/graphic/88939.html" rel="external">table 3</a>). (See <a class="local">'Heterozygous FH (HeFH)'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>HoFH</strong> – HoFH should be suspected in patients with markedly elevated cholesterol levels (ie, untreated LDL-C &gt;500 mg/dL [&gt;13 mmol/L] or treated LDL-C ≥300 mg/dL [&gt;8 mmol/L]) in combination with cutaneous or tendon xanthoma before age 10 years and/or elevated cholesterol levels in both parents. A definitive diagnosis is made by identifying causative mutations in the LDL receptor (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F606945&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdyqZvH8B67zc54PCoQNakQYi&amp;TOPIC_ID=121831" target="_blank">LDLR</a>), apolipoprotein B (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F107730&amp;token=tEpDslnpc0F0kICl%2Fz7sFc8JblQ%2BgdQqT9K%2Br8tS8tjdlf01kAfyT8%2B%2FbsYKwVdF&amp;TOPIC_ID=121831" target="_blank">APOB</a>), or proprotein convertase subtilisin/kexin type 9 (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F607786&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdyqAswF%2Bh2WgQ41BBcelnzoq&amp;TOPIC_ID=121831" target="_blank"><i>PCSK9</i></a>) genes. (See <a class="local">'Homozygous FH (HoFH)'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differential diagnosis</strong> – FH can be distinguished from other causes of hypercholesterolemia, xanthomata, and premature atherosclerotic CVD on the basis of the family and clinical history, physical examination, lipid profile, and genetic testing  (<a class="graphic graphic_table graphicRef66747" href="/d/graphic/66747.html" rel="external">table 4</a>). (See <a class="local">'Differential diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong> </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>HeFH</strong> – For children and adolescents with HeFH, a combination of lifestyle and medical management is generally required to sufficiently lower LDL-C. The goal of treatment is to reduce LDL-C minimally to a level &lt;130 mg/dL (3.4 mmol/L) and ideally &lt;100 mg/dL (2.6 mmol/L). (See <a class="local">'Treatment goals'</a> above.)</p><p></p><p class="bulletIndent2">The initial management approach for pediatric patients with HeFH is generally similar to the management of other causes of pediatric hypercholesterolemia, though there are some distinctions as outlined above. (See <a class="local">'Key distinctions between HeFH and other types of dyslipidemia'</a> above.) </p><p></p><p class="bulletIndent2">The management approach is summarized in the algorithms  (<a class="graphic graphic_algorithm graphicRef106010 graphicRef106011" href="/d/graphic/106010.html" rel="external">algorithm 2A-B</a>) and discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/17048.html" rel="external">"Dyslipidemia in children and adolescents: Management", section on 'Hypercholesterolemia'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>HoFH</strong> – Children with HoFH should be managed by a pediatric lipid specialist and a pediatric cardiologist. Management includes (see <a class="local">'Management of HoFH'</a> above):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Comprehensive cardiovascular evaluation</strong> – The evaluation at initial diagnosis and at periodic follow-up includes electrocardiogram, echocardiography, stress testing (if the child is old enough to cooperate), and coronary angiography by computed tomography or cardiac catheterization.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Prompt and aggressive lipid-lowering therapy</strong> – Management is carried out in a stepwise fashion targeting a goal LDL-C value of &lt;135 mg/dL (3.5 mmol/L). For all individuals with HoFH, we recommend initiating high-potency statin therapy in addition to lifestyle advice at the time of diagnosis (<a class="grade" href="https://medilib.ir/uptodate/show/grade_2" rel="external">Grade 1B</a>). For most patients, we suggest adding <a class="drug drug_pediatric" data-topicid="12909" href="/d/drug information/12909.html" rel="external">ezetimibe</a> as the second lipid-lowering agent (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>). Additional treatments are invariably required. These include anti-<em>PCSK9</em> therapy (if there is any LDL receptor function), LDL apheresis, <a class="drug drug_pediatric" data-topicid="130801" href="/d/drug information/130801.html" rel="external">evinacumab</a>, and <a class="drug drug_general" data-topicid="87508" href="/d/drug information/87508.html" rel="external">lomitapide</a>. (See  <a class="medical medical_review" href="/d/html/17048.html" rel="external">"Dyslipidemia in children and adolescents: Management", section on 'Second-line agents and other therapies'</a> and  <a class="medical medical_review" href="/d/html/4554.html" rel="external">"Treatment of drug-resistant hypercholesterolemia"</a>.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Appropriate medical management of CAD</strong> – For children with clinically significant CAD, we suggest treatment with low-dose <a class="drug drug_pediatric" data-topicid="12829" href="/d/drug information/12829.html" rel="external">aspirin</a> and beta blocker therapy (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>). This is based on the established benefits of these drugs in adults with CAD. (See  <a class="medical medical_review" href="/d/html/110006.html" rel="external">"Aspirin for the secondary prevention of atherosclerotic cardiovascular disease"</a> and  <a class="medical medical_review" href="/d/html/1466.html" rel="external">"Beta blockers in the management of chronic coronary syndrome"</a>.)</p><p></p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Nordestgaard BG, Chapman MJ, Humphries SE, et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J 2013; 34:3478.</a></li><li><a class="nounderline abstract_t">de Ferranti SD, Rodday AM, Mendelson MM, et al. Prevalence of Familial Hypercholesterolemia in the 1999 to 2012 United States National Health and Nutrition Examination Surveys (NHANES). Circulation 2016; 133:1067.</a></li><li><a class="nounderline abstract_t">Benn M, Watts GF, Tybjaerg-Hansen A, Nordestgaard BG. Familial hypercholesterolemia in the danish general population: prevalence, coronary artery disease, and cholesterol-lowering medication. J Clin Endocrinol Metab 2012; 97:3956.</a></li><li><a class="nounderline abstract_t">Hu P, Dharmayat KI, Stevens CAT, et al. Prevalence of Familial Hypercholesterolemia Among the General Population and Patients With Atherosclerotic Cardiovascular Disease: A Systematic Review and Meta-Analysis. Circulation 2020; 141:1742.</a></li><li><a class="nounderline abstract_t">Sjouke B, Kusters DM, Kindt I, et al. Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotype-phenotype relationship, and clinical outcome. Eur Heart J 2015; 36:560.</a></li><li><a class="nounderline abstract_t">Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents, National Heart, Lung, and Blood Institute. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report. Pediatrics 2011; 128 Suppl 5:S213.</a></li><li><a class="nounderline abstract_t">Wiegman A, Gidding SS, Watts GF, et al. Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment. Eur Heart J 2015; 36:2425.</a></li><li><a class="nounderline abstract_t">Gidding SS, Champagne MA, de Ferranti SD, et al. The Agenda for Familial Hypercholesterolemia: A Scientific Statement From the American Heart Association. Circulation 2015; 132:2167.</a></li><li><a class="nounderline abstract_t">Wierzbicki AS, Humphries SE, Minhas R, Guideline Development Group. Familial hypercholesterolaemia: summary of NICE guidance. BMJ 2008; 337:a1095.</a></li><li><a class="nounderline abstract_t">Cuchel M, Bruckert E, Ginsberg HN, et al. Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. Eur Heart J 2014; 35:2146.</a></li><li><a class="nounderline abstract_t">Gregg RE, Connor WE, Lin DS, Brewer HB Jr. Abnormal metabolism of shellfish sterols in a patient with sitosterolemia and xanthomatosis. J Clin Invest 1986; 77:1864.</a></li><li class="breakAll">Hoffman EP, Barr ML, et al. Lysosomal Acid Lipase Deficiency. GeneReviews. Available at: https://www.ncbi.nlm.nih.gov/books/NBK305870/ (Accessed on September 01, 2016).</li><li><a class="nounderline abstract_t">de Ferranti SD, Steinberger J, Ameduri R, et al. Cardiovascular Risk Reduction in High-Risk Pediatric Patients: A Scientific Statement From the American Heart Association. Circulation 2019; 139:e603.</a></li><li><a class="nounderline abstract_t">Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2019; 139:e1082.</a></li><li><a class="nounderline abstract_t">Rodenburg J, Vissers MN, Wiegman A, et al. Statin treatment in children with familial hypercholesterolemia: the younger, the better. Circulation 2007; 116:664.</a></li><li><a class="nounderline abstract_t">Kusters DM, Wiegman A, Kastelein JJ, Hutten BA. Carotid intima-media thickness in children with familial hypercholesterolemia. Circ Res 2014; 114:307.</a></li><li><a class="nounderline abstract_t">Braamskamp MJAM, Langslet G, McCrindle BW, et al. Effect of Rosuvastatin on Carotid Intima-Media Thickness in Children With Heterozygous Familial Hypercholesterolemia: The CHARON Study (Hypercholesterolemia in Children and Adolescents Taking Rosuvastatin Open Label). Circulation 2017; 136:359.</a></li><li><a class="nounderline abstract_t">Avis HJ, Vissers MN, Stein EA, et al. A systematic review and meta-analysis of statin therapy in children with familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 2007; 27:1803.</a></li><li><a class="nounderline abstract_t">Vuorio A, Kuoppala J, Kovanen PT, et al. Statins for children with familial hypercholesterolemia. Cochrane Database Syst Rev 2017; 7:CD006401.</a></li><li><a class="nounderline abstract_t">Luirink IK, Wiegman A, Kusters DM, et al. 20-Year Follow-up of Statins in Children with Familial Hypercholesterolemia. N Engl J Med 2019; 381:1547.</a></li><li><a class="nounderline abstract_t">Wiegman A, Hutten BA, de Groot E, et al. Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized controlled trial. JAMA 2004; 292:331.</a></li><li><a class="nounderline abstract_t">Kusters DM, Avis HJ, de Groot E, et al. Ten-year follow-up after initiation of statin therapy in children with familial hypercholesterolemia. JAMA 2014; 312:1055.</a></li><li><a class="nounderline abstract_t">de Jongh S, Lilien MR, op't Roodt J, et al. Early statin therapy restores endothelial function in children with familial hypercholesterolemia. J Am Coll Cardiol 2002; 40:2117.</a></li><li><a class="nounderline abstract_t">Kastelein JJ, Akdim F, Stroes ES, et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 2008; 358:1431.</a></li><li><a class="nounderline abstract_t">van der Graaf A, Cuffie-Jackson C, Vissers MN, et al. Efficacy and safety of coadministration of ezetimibe and simvastatin in adolescents with heterozygous familial hypercholesterolemia. J Am Coll Cardiol 2008; 52:1421.</a></li><li class="breakAll">https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125522s029s031lbl.pdf (Accessed on September 30, 2021).</li><li class="breakAll">European Medicines Agency, Summary of opinion: Repatha (evolocumab), available at: http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/human/003766/WC500187093.pdf (Accessed on August 20, 2015).</li><li><a class="nounderline abstract_t">Santos RD, Ruzza A, Hovingh GK, et al. Evolocumab in Pediatric Heterozygous Familial Hypercholesterolemia. N Engl J Med 2020; 383:1317.</a></li><li><a class="nounderline abstract_t">Luirink IK, Kuipers IM, Hutten BA, et al. Coronary computed tomography angiography and echocardiography in children with homozygous familial hypercholesterolemia. Atherosclerosis 2019; 285:87.</a></li><li><a class="nounderline abstract_t">Reeskamp LF, Nurmohamed NS, Bom MJ, et al. Marked plaque regression in homozygous familial hypercholesterolemia. Atherosclerosis 2021; 327:13.</a></li><li><a class="nounderline abstract_t">Gaudet D, Gipe DA, Pordy R, et al. ANGPTL3 Inhibition in Homozygous Familial Hypercholesterolemia. N Engl J Med 2017; 377:296.</a></li><li><a class="nounderline abstract_t">Raal FJ, Rosenson RS, Reeskamp LF, et al. Evinacumab for Homozygous Familial Hypercholesterolemia. N Engl J Med 2020; 383:711.</a></li><li><a class="nounderline abstract_t">Qiu HR, Zhang L, Zhu ZJ. Perioperative Management and Clinical Outcomes of Liver Transplantation for Children with Homozygous Familial Hypercholesterolemia. Medicina (Kaunas) 2022; 58.</a></li></ol></div><div id="topicVersionRevision">Topic 121831 Version 8.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23956253" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26976914" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Prevalence of Familial Hypercholesterolemia in the 1999 to 2012 United States National Health and Nutrition Examination Surveys (NHANES).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22893714" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Familial hypercholesterolemia in the danish general population: prevalence, coronary artery disease, and cholesterol-lowering medication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32468833" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Prevalence of Familial Hypercholesterolemia Among the General Population and Patients With Atherosclerotic Cardiovascular Disease: A Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24585268" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotype-phenotype relationship, and clinical outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22084329" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26009596" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26510694" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : The Agenda for Familial Hypercholesterolemia: A Scientific Statement From the American Heart Association.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18753174" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Familial hypercholesterolaemia: summary of NICE guidance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25053660" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3711338" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Abnormal metabolism of shellfish sterols in a patient with sitosterolemia and xanthomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3711338" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Abnormal metabolism of shellfish sterols in a patient with sitosterolemia and xanthomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30798614" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Cardiovascular Risk Reduction in High-Risk Pediatric Patients: A Scientific Statement From the American Heart Association.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30586774" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17664376" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Statin treatment in children with familial hypercholesterolemia: the younger, the better.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24192652" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Carotid intima-media thickness in children with familial hypercholesterolemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28592434" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Effect of Rosuvastatin on Carotid Intima-Media Thickness in Children With Heterozygous Familial Hypercholesterolemia: The CHARON Study (Hypercholesterolemia in Children and Adolescents Taking Rosuvastatin Open Label).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17569881" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : A systematic review and meta-analysis of statin therapy in children with familial hypercholesterolemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28685504" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Statins for children with familial hypercholesterolemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31618540" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : 20-Year Follow-up of Statins in Children with Familial Hypercholesterolemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15265847" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25203086" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Ten-year follow-up after initiation of statin therapy in children with familial hypercholesterolemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12505222" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Early statin therapy restores endothelial function in children with familial hypercholesterolemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18376000" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Simvastatin with or without ezetimibe in familial hypercholesterolemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18940534" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Efficacy and safety of coadministration of ezetimibe and simvastatin in adolescents with heterozygous familial hypercholesterolemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18940534" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Efficacy and safety of coadministration of ezetimibe and simvastatin in adolescents with heterozygous familial hypercholesterolemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18940534" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Efficacy and safety of coadministration of ezetimibe and simvastatin in adolescents with heterozygous familial hypercholesterolemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32865373" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Evolocumab in Pediatric Heterozygous Familial Hypercholesterolemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31048103" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Coronary computed tomography angiography and echocardiography in children with homozygous familial hypercholesterolemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34004483" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Marked plaque regression in homozygous familial hypercholesterolemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28723334" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : ANGPTL3 Inhibition in Homozygous Familial Hypercholesterolemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32813947" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Evinacumab for Homozygous Familial Hypercholesterolemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36295590" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Perioperative Management and Clinical Outcomes of Liver Transplantation for Children with Homozygous Familial Hypercholesterolemia.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
